- Exchange: Oslo
- Sector: Consumer, Non-cyclical
- Industry: Pharmaceuticals
- Sub-Industry: Therapeutics
Snapshot for Algeta ASA (ALGETA)
| Open: | 209.80 | Day's Range: | 206.60 - 210.00 | Volume: | 125,701 |
|---|---|---|---|---|---|
| Previous Close: | 209.00 | 52wk Range: | 131.00 - 245.40 | 1-Yr Rtn: | +47.70% |
Key Statistics for ALGETA
| Current P/E Ratio (ttm) | 50.9834 |
|---|---|
| Estimated P/E(12/2013) | - |
| Relative P/E vs. OBX | 3.7636 |
| Earnings Per Share (NOK) (ttm) | 4.0994 |
| Est. EPS (NOK) (12/2013) | -0.7700 |
| Est. PEG Ratio | - |
| Market Cap (M NOK) | 9,148.28 |
| Shares Outstanding (M) | 43.77 |
| 30 Day Average Volume | 158,996 |
| Price/Book (mrq) | 11.7725 |
| Price/Sale (ttm) | 14.1928 |
| Dividend Indicated Gross Yield | -% |
| Cash Dividend | - |
| Last Dividend | |
| 5 Year Dividend Growth | - |
| Next Earnings Announcement | 08/28/2013 |
mrq = Most Recent Quarter; ttm = Trailing Twelve Months
Income Statement for ALGETA
Company Profile & Key Executives for ALGETA
Algeta ASA operates in the pharmaceutical industry. The Company develops targeted therapies for patients with cancer based on its alpha-pharmaceutical platform. Algeta's compound Alpharadin is designed to treat bone metastases.
| Stein Holst AnnexstadChairman | John Edward BerrimanDeputy Chairman |
| Andrew Martin KayPresident/CEO | Oystein SougChief Financial Officer |
Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.
Sponsored Financial Commentaries
Advertisement
Top Forex Trading Resources
-
ALGETA News
-
Industry News
Advertisement
Advertisement
Sponsored Links
Advertisements
Rate this Page